Bridgebio Pharma Inc (BBIO)

$26.18

-0.77

(-2.86%)▲

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $25.97
    $27.32
    $26.18
    downward going graph

    0.8%

    Downside

    Day's Volatility :4.92%

    Upside

    4.16%

    downward going graph
  • $21.62
    $44.32
    $26.18
    downward going graph

    17.42%

    Downside

    52 Weeks Volatility :51.22%

    Upside

    40.93%

    downward going graph

Returns

PeriodBridgebio Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
-6.03%
7.0%
0.0%
6 Months
-4.28%
7.0%
0.0%
1 Year
-11.61%
17.2%
0.0%
3 Years
-46.28%
18.0%
-20.0%

Highlights

Market Capitalization
5.1B
Book Value
- $5.81
Earnings Per Share (EPS)
-2.57
Wall Street Target Price
48.46
Profit Margin
-207.11%
Operating Margin TTM
-7963.47%
Return On Assets TTM
-48.44%
Return On Equity TTM
-1789.67%
Revenue TTM
219.1M
Revenue Per Share TTM
1.25
Quarterly Revenue Growth YOY
32.1%
Gross Profit TTM
74.2M
EBITDA
-496.6M
Diluted Eps TTM
-2.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.77
EPS Estimate Next Year
-3.12
EPS Estimate Current Quarter
-1.04
EPS Estimate Next Quarter
-1.05

Analyst Recommendation

Buy
    85%Buy
    15%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Bridgebio Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
16
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 85.1%

Current $26.18
Target $48.46

Technicals Summary

Sell

Neutral

Buy

Bridgebio Pharma Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bridgebio Pharma Inc
Bridgebio Pharma Inc
7.96%
-4.28%
-11.61%
-46.28%
3.15%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.3%
20.26%
38.56%
78.77%
303.42%
Novo Nordisk A/s
Novo Nordisk A/s
1.92%
1.8%
42.06%
173.92%
453.76%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
0.91%
78.6%
37.4%
41.12%
212.93%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.95%
18.74%
38.91%
157.61%
173.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bridgebio Pharma Inc
Bridgebio Pharma Inc
NA
NA
NA
-1.77
-17.9
-0.48
NA
-5.81
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.86
30.86
1.59
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
46.01
46.01
2.08
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bridgebio Pharma Inc
Bridgebio Pharma Inc
Buy
$5.1B
3.15%
NA
-207.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$128.4B
303.42%
30.86
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$600.4B
453.76%
46.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.1B
212.93%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$125.3B
173.37%
32.84
-4.74%

Insights on Bridgebio Pharma Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 211.12M → 2.16M (in $), with an average decrease of 99.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -35.21M → -73.45M (in $), with an average decrease of 108.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 53.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 173.9% return, outperforming this stock by 220.2%

Institutional Holdings

  • Kohlberg Kravis Roberts & Co LP

    16.52%

  • Viking Global Investors LP

    13.36%

  • Vanguard Group Inc

    7.47%

  • BlackRock Inc

    6.62%

  • Aisling Capital Management LP

    3.23%

  • State Street Corp

    3.11%

Corporate Announcements

  • Bridgebio Pharma Inc Earnings

    Bridgebio Pharma Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Organization
Bridgebio Pharma Inc
Employees
550
CEO
Dr. Neil Kumar Ph.D.
Industry
Health Technology

Discover More

FAQs